3REGN : Price Over Earnings Overview: Regeneron Pharmaceuticals
In the current market session, Regeneron Pharmaceuticals Inc. REGN share price is at $695.58, after a 0.06% decrease. Over the past month, the stock spiked by 2.93%, but over the past year, it ...
stocknews3h
3 Precision Medicine Stocks That Could Transform Healthcare
With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...
JD Supra7h
First Circuit Requires But-For Causation for FCA Liability Based on AKS Violations
Key Takeaways - The First Circuit ruled in United States v. Regeneron Pharmaceuticals, Inc., that the government must prove but-for causation ...
JD Supra1h
First Circuit Adopts “But-For” Causation Standard for Proving Kickback FCA Violations
In a closely watched appeal, the U.S. Court of Appeals for the First Circuit ruled on February 18 that to satisfy the causation requirement in ...
Healio6h
FDA accepts sBLA, grants priority review for Dupixent to treat bullous pemphigoid
The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...
American Century Ultra Fund Q4 2024 Commentary
The reelection of former President Donald Trump initially pleased investors who had worried about another protracted legal ...
Hosted on MSN7h
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...
Hosted on MSN8h
2 Healthcare Stocks with Big Upside and 1 to Skip
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But ...
pharmaphorum22h
And then there were none: Regeneron cans last late-stage NGF drug
Regeneron also said it was discontinuing a phase 3 study of REGN1908-1909, a multi-antibody therapy to Fel d 1 being studied as a treatment for cat allergy, due to futility. Image Phil Taylor ...